13F Holdings
中文EN

VSTM Verastem, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1526119 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY25.8%
TTM EPS YoY57.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-193.7%
Net margin-178.4%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-88.0%
ROIC (approx.)—
Asset turnover0.49x

Leverage & solvency

Liabilities / assets95.6%
Debt / equity0.00x
Current ratio1.93x
Interest coverage-141.93x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$30.91M$10.00M—$2.60M$2.05M
R&D expense$114.60M$81.33M$61.36M$50.56M$39.35M
SG&A expense$81.15M$43.62M$30.73M$24.98M$24.11M
Operating income-$170.13M-$114.96M-$92.08M-$72.94M-$61.41M
Interest expense$1.14M$4.56M$4.14M$2.14M$9.97M
Pretax income-$209.47M-$130.45M-$87.37M-$73.81M-$71.20M
Income tax—$185,000—$0$0
Net income-$209.47M-$130.64M-$87.37M-$73.81M-$71.20M
EBITDA-$170.10M-$114.93M-$92.02M-$72.82M-$61.20M
EPS (basic)-3.02-3.66-3.96-4.57-4.90
EPS (diluted)-3.02-3.66-3.96-4.57-4.90
Weighted avg. shares (diluted)69.31M35.71M22.05M16.14M14.54M
Balance sheet
Cash & equivalents$204.99M$89.06M$79.08M$75.79M$21.49M
Short-term investments——$59.22M$12.96M$79.00M
Inventory$1.83M————
Current assets$223.41M$94.96M$143.68M$92.87M$105.74M
PP&E, net—$32,000$37,000$92,000$210,000
Intangibles$16.43M————
Total assets$246.44M$101.54M$149.72M$95.05M$108.66M
Current liabilities$72.27M$30.97M$26.38M$21.66M$18.59M
Long-term debt—$40.72M$40.09M$24.53M—
Total debt—$40.72M$40.09M$24.53M—
Total liabilities$189.25M$130.43M$71.19M$47.66M$21.10M
Shareholders' equity$57.20M-$28.89M$57.37M$47.39M$87.56M
Net debt—-$48.34M-$38.99M-$51.26M—
Shares outstanding77.74M44.78M25.28M16.71M185.29M
Cash flow statement
Operating cash flow-$137.51M-$104.77M-$86.46M-$63.67M-$53.50M
Capital expenditure—$28,000——$196,000
Free cash flow—-$104.80M——-$53.70M
Investing cash flow-$9.62M$59.97M-$44.45M$66.19M$87,000
Financing cash flow$263.31M$54.78M$134.19M$51.78M$6.88M
Depreciation & amortization$30,000$26,000$62,000$118,000$206,000
Stock-based compensation$9.40M$7.34M$5.86M$6.05M$7.71M

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.